Empagd

Therapeutic Segment:
Anti-diabetic

Generic Name:
Empagliflozin

Description:
Empagd tablets contain empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Each film-coated tablet of Empagd contains 10mg or 25mg of empagliflozin (free base).

Indication:

  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use:
  • Empagd is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Formulation:

  • Tablets

Strength:

  • 10MG
  • 25MG

Pack Size:

  • 1 x14’s
  • 2 x 7’s
Empagd-packshot-copy